Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1477-7819
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report ; volume:20 ; number:1 ; day:12 ; month:7 ; year:2022 ; pages:1-6 ; date:12.2022
World journal of surgical oncology ; 20, Heft 1 (12.7.2022), 1-6, 12.2022
- Creator
-
Hidaka, Yoshifumi
Tomita, Miyo
Desaki, Ryosuke
Hamanoue, Masahiro
Takao, Sonshin
Kirishima, Mari
Ohtsuka, Takao
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12957-022-02691-2
- URN
-
urn:nbn:de:101:1-2022091521372316384082
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hidaka, Yoshifumi
- Tomita, Miyo
- Desaki, Ryosuke
- Hamanoue, Masahiro
- Takao, Sonshin
- Kirishima, Mari
- Ohtsuka, Takao
- SpringerLink (Online service)
Other Objects (12)
Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma
Vein graft aneurysm with mural thrombus on echocardiography
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150
Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience
Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma
Vein graft aneurysm with mural thrombus on echocardiography
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150
Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience
Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma
Vein graft aneurysm with mural thrombus on echocardiography
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150